The Food and Drug Administration’s (FDA) Oncology Drug Advisory Committee (ODAC) is meeting today to discuss whether the labels for Erbitux (cetuximab) and Vectibix (panitumumab) should include a mention of KRAS testing. The discussion at the meeting will have implications for future development of companion diagnostics. C3 President Carlea Bauman will be testifying during the public comment section: Read the rest of this entry »
Take the Million Strong Pledge
Stay In Touch – Sign Up
Sign up to receive our free monthly eNews, webinar topics, and special events for patients, care givers and advocates - We Need YOU!
*These fields are required.
-The Challenge Phrase is case sensitive. We use this to prevent spammers. Please type carefully.
Thanks for your understanding.